Cost-Utility of Real-Time Potassium Monitoring in United States Patients Receiving Hemodialysis
Introduction: Patients with kidney failure requiring hemodialysis are at high risk for hyperkalemia between treatments, which is associated with increased cardiovascular morbidity and mortality. Early detection of hyperkalemic events may be useful to prevent adverse outcomes and their associated cos...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-11-01
|
| Series: | Kidney International Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024924018795 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849690918857211904 |
|---|---|
| author | Ryan J. Bamforth Thomas W. Ferguson Navdeep Tangri Claudio Rigatto David Collister Paul Komenda |
| author_facet | Ryan J. Bamforth Thomas W. Ferguson Navdeep Tangri Claudio Rigatto David Collister Paul Komenda |
| author_sort | Ryan J. Bamforth |
| collection | DOAJ |
| description | Introduction: Patients with kidney failure requiring hemodialysis are at high risk for hyperkalemia between treatments, which is associated with increased cardiovascular morbidity and mortality. Early detection of hyperkalemic events may be useful to prevent adverse outcomes and their associated costs. We performed a cost-utility analysis comparing an intervention where a real-time potassium monitoring device is administered in patients on hemodialysis in comparison to usual care. Methods: We developed a cost-utility model with microsimulation from the perspective of the United States health care payer. Primary outcomes included the monthly cost-effectiveness threshold cost and break-even cost per patient attributable to the intervention and the incremental cost-effectiveness ratio comparing the intervention to usual care. A 25% reduction in hyperkalemic events was applied as a baseline device effectiveness estimate. Concurrent first and second order microsimulations were performed using 10%, 25%, and 50% effectiveness estimates as sensitivity analyses. Results are presented over a 10-year time horizon in 2022 United States dollars and a willingness-to-pay threshold of $100,000 per quality-adjusted life year (QALY) was considered. Results: Over 10 years, threshold and break-even analysis yielded maximum monthly costs of $201.10 and $144.15 per patient, respectively. The intervention was associated with reduced mean costs ($6381.21) and increased mean QALYs (0.03) per patient; therefore, was considered dominant. In sensitivity analysis, the intervention was dominant in 99% of simulations performed at all effectiveness rates. Conclusion: Implementing a real-time potassium monitoring device in patients on hemodialysis has the potential for cost savings and improved outcomes from the perspective of the United States health care payer. |
| format | Article |
| id | doaj-art-65f93daf10e34f6daca71e950b01ee3c |
| institution | DOAJ |
| issn | 2468-0249 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Kidney International Reports |
| spelling | doaj-art-65f93daf10e34f6daca71e950b01ee3c2025-08-20T03:21:11ZengElsevierKidney International Reports2468-02492024-11-019113226323510.1016/j.ekir.2024.08.007Cost-Utility of Real-Time Potassium Monitoring in United States Patients Receiving HemodialysisRyan J. Bamforth0Thomas W. Ferguson1Navdeep Tangri2Claudio Rigatto3David Collister4Paul Komenda5Chronic Disease Innovation Centre, Winnipeg, Manitoba, CanadaChronic Disease Innovation Centre, Winnipeg, Manitoba, CanadaChronic Disease Innovation Centre, Winnipeg, Manitoba, Canada; Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, CanadaChronic Disease Innovation Centre, Winnipeg, Manitoba, Canada; Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, CanadaDivision of Nephrology, Department of Medicine, Faculty of Medicine and Dentistry, Edmonton, Alberta. CanadaChronic Disease Innovation Centre, Winnipeg, Manitoba, Canada; Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada; Correspondence: Paul Komenda, Seven Oaks General Hospital, 2LB10-2300 McPhillips Street, Winnipeg, Manitoba R2V 3M3, Canada.Introduction: Patients with kidney failure requiring hemodialysis are at high risk for hyperkalemia between treatments, which is associated with increased cardiovascular morbidity and mortality. Early detection of hyperkalemic events may be useful to prevent adverse outcomes and their associated costs. We performed a cost-utility analysis comparing an intervention where a real-time potassium monitoring device is administered in patients on hemodialysis in comparison to usual care. Methods: We developed a cost-utility model with microsimulation from the perspective of the United States health care payer. Primary outcomes included the monthly cost-effectiveness threshold cost and break-even cost per patient attributable to the intervention and the incremental cost-effectiveness ratio comparing the intervention to usual care. A 25% reduction in hyperkalemic events was applied as a baseline device effectiveness estimate. Concurrent first and second order microsimulations were performed using 10%, 25%, and 50% effectiveness estimates as sensitivity analyses. Results are presented over a 10-year time horizon in 2022 United States dollars and a willingness-to-pay threshold of $100,000 per quality-adjusted life year (QALY) was considered. Results: Over 10 years, threshold and break-even analysis yielded maximum monthly costs of $201.10 and $144.15 per patient, respectively. The intervention was associated with reduced mean costs ($6381.21) and increased mean QALYs (0.03) per patient; therefore, was considered dominant. In sensitivity analysis, the intervention was dominant in 99% of simulations performed at all effectiveness rates. Conclusion: Implementing a real-time potassium monitoring device in patients on hemodialysis has the potential for cost savings and improved outcomes from the perspective of the United States health care payer.http://www.sciencedirect.com/science/article/pii/S2468024924018795cost-utilitydialysishemodialysishyperkalemiapotassium |
| spellingShingle | Ryan J. Bamforth Thomas W. Ferguson Navdeep Tangri Claudio Rigatto David Collister Paul Komenda Cost-Utility of Real-Time Potassium Monitoring in United States Patients Receiving Hemodialysis Kidney International Reports cost-utility dialysis hemodialysis hyperkalemia potassium |
| title | Cost-Utility of Real-Time Potassium Monitoring in United States Patients Receiving Hemodialysis |
| title_full | Cost-Utility of Real-Time Potassium Monitoring in United States Patients Receiving Hemodialysis |
| title_fullStr | Cost-Utility of Real-Time Potassium Monitoring in United States Patients Receiving Hemodialysis |
| title_full_unstemmed | Cost-Utility of Real-Time Potassium Monitoring in United States Patients Receiving Hemodialysis |
| title_short | Cost-Utility of Real-Time Potassium Monitoring in United States Patients Receiving Hemodialysis |
| title_sort | cost utility of real time potassium monitoring in united states patients receiving hemodialysis |
| topic | cost-utility dialysis hemodialysis hyperkalemia potassium |
| url | http://www.sciencedirect.com/science/article/pii/S2468024924018795 |
| work_keys_str_mv | AT ryanjbamforth costutilityofrealtimepotassiummonitoringinunitedstatespatientsreceivinghemodialysis AT thomaswferguson costutilityofrealtimepotassiummonitoringinunitedstatespatientsreceivinghemodialysis AT navdeeptangri costutilityofrealtimepotassiummonitoringinunitedstatespatientsreceivinghemodialysis AT claudiorigatto costutilityofrealtimepotassiummonitoringinunitedstatespatientsreceivinghemodialysis AT davidcollister costutilityofrealtimepotassiummonitoringinunitedstatespatientsreceivinghemodialysis AT paulkomenda costutilityofrealtimepotassiummonitoringinunitedstatespatientsreceivinghemodialysis |